profit from every $100 of sales.
$0$100
Ultragenyx Pharmaceutical
$16.08-1.17% today
-51.1% in 1 year
1-year low $12.881-year high $36.54
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Ultragenyx Pharmaceutical sold, what it kept, and what it did with the cash.
Sales went from $363 million in 2022 to $673 million in 2025, with -$575 million of profit last year.
SalesProfit
Ultragenyx Pharmaceutical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ultragenyx Pharmaceutical | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Ultragenyx Pharmaceutical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 363 | 434 | 560 | 673 | |
| 335 | 389 | 483 | 564 | |
| -649 | -569 | -536 | -535 | |
| -640 | -517 | -468 | -474 | |
| -707 | -607 | -569 | -575 | |
| -10.12 | -8.25 | -6.29 | -5.83 | |
| 92.2% | 89.6% | 86.3% | 83.8% | |
| -178.6% | -131.1% | -95.7% | -79.5% | |
| -194.7% | -139.9% | -101.6% | -85.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,545 | 1,491 | 1,503 | 1,532 |
| Cash | 133 | 214 | 174 | 421 |
| Total debt | 32 | 43 | 40 | 36 |
| Total liabilities | 1,193 | 1,216 | 1,241 | 1,605 |
| 352 | 275 | 255 | -80 | |
| 70 | 74 | 91 | 99 | |
| -135.5% | -134.6% | -135.0% | – | |
| -200.7% | -220.4% | -223.1% | 718.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -380 | -475 | -414 | -466 | |
| 146 | 47 | 20 | 21 | |
| -527 | -522 | -434 | -487 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 130 | 135 | 158 | 153 |
Valuation
- –
- –
- –
- -10.2×
- 2.4×
- –
- –
- -29.7%
- -35.1%
- 0.0%
Profitability
- 83.8%
- -79.5%
- -85.4%
- -76.8%
- -53.9%
- -132.5%
- 1,566.9%
- -47.0%
- -57.9%
- 115.2%
Growth
- +22.8%
- –
- −11.9%
- –
- +9.8%
Financial health
- -0.8×
- -5.08
- 92.6%
- -8.2×
- 2.02
- 1.85
- 0.52
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 952
Bottom 5%of 884
Top 24%of 886
Bottom 2%of 987
What analysts expect
- Average price target
- $51.50
- Range
- $34.00 – $67.00
- 8 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -1.84 | -1.49 | −23.7% |
| Feb 12, 2026 | -1.29 | -1.20 | −7.5% |
| Nov 4, 2025 | -1.81 | -1.23 | −47.2% |
| Aug 5, 2025 | -1.17 | -1.27 | +7.9% |
| May 6, 2025 | -1.57 | -1.54 | −1.9% |
| Feb 13, 2025 | -1.39 | -1.32 | −5.3% |
| Nov 5, 2024 | -1.40 | -1.45 | +3.4% |
| Aug 1, 2024 | -1.52 | -1.64 | +7.3% |
News
U.S. air travel could take days to recover after FAA’s lifting of rare nationwide ground stopMarketWatch · Nov 14, 2026Can USA Rare Earth Stock Jump 10X?Yahoo Finance · Nov 12, 2026Every Humanoid Robot Needs Rare-Earth Magnets. Here's the American Stock Positioned to Sell Them -- and It's Down 62%.Yahoo Finance · Nov 7, 2026’Blue tsunami’ batters AI stocks: Is this a rare buy the dip setup?Yahoo Finance · Nov 6, 2026Here's What $5,000 in USA Rare Earth Could Be Worth by 2030 If It Reaches MP Materials' Market CapYahoo Finance · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
28No pass
Philip Fisher
51No pass
Peter Lynch
57No pass
Joel Greenblatt
2No pass
Charlie Munger
38No pass
Terry Smith
43No pass
Questions about Ultragenyx Pharmaceutical
Is Ultragenyx Pharmaceutical a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ultragenyx Pharmaceutical AI analysis
What does Ultragenyx Pharmaceutical do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. It is in Biotechnology.
Does Ultragenyx Pharmaceutical pay a dividend?
No. Ultragenyx Pharmaceutical does not pay a dividend at the moment.
Is Ultragenyx Pharmaceutical stock halal?
No. Ultragenyx Pharmaceutical does not pass our halal screen: its cash and confirmed interest-bearing investments are 42% of its market value, at or above the 33% limit. How we check
How has Ultragenyx Pharmaceutical stock done over the past year?
Down 51.1% over the past twelve months, to $16.08. It traded between $12.88 and $36.54 and is 56.0% below its high.
Who are Ultragenyx Pharmaceutical's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Ultragenyx Pharmaceutical's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.